Gene therapy study for high-grade glioma
Part of Cancer clinical trials.
This trial tests a new gene therapy given directly into the brain tumor. It's for people with high-grade glioma, either newly diagnosed or after one recurrence, to see if it can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and have a high-grade glioma (a type of aggressive brain tumor).
- You can still take care of most daily activities (Karnofsky score of 70 or higher).
- If you are newly diagnosed, you haven't had any other treatments for your brain tumor yet, and you're a candidate for standard chemoradiation therapy followed by temozolomide.
- If your tumor has come back, you've only had one recurrence after previous treatment with surgery, radiation, and chemotherapy.
- You are able to take pills by mouth, agree to use effective birth control (if applicable), and avoid live vaccines during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
This trial tests a new gene therapy that uses two special viruses and an oral antiviral drug (valacyclovir) to treat brain tumors that have come back in children and young adults. The therapy is given right after surgery to remove the tumor, with the goal of helping your immune system fight the cancer.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.